FDA Grants Dasatinib Priority Review for Resistant CML

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 4
Volume 15
Issue 4

The FDA has granted priority review to dasatinib (BMS-354825), developed by Bristol-Myers Squibb, for treatment of imatinib (Gleevec)-resistant or refractory chronic myelogenous leukemia (CML) in adults.

PRINCETON, New Jersey—The FDA has granted priority review to dasatinib (BMS-354825), developed by Bristol-Myers Squibb, for treatment of imatinib (Gleevec)-resistant or refractory chronic myelogenous leukemia (CML) in adults. Dasatinib, an oral, small-molecule tyrosine kinase inhibitor, exhibits greater potency than imatinib and inhibits the majority of kinase mutations resistant to imatinib. The new drug application also seeks approval of dasatinib for treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.

Articles in this issue
Phase II Trial of Velcade/Alimta Initiated in Advanced NSCLC
ONS Annual Congress Heralds Start of Oncology Nursing Month
All-Star Panel Spells Out Onc Promises, Problems
Surveillance for Colon, Breast Ca Falls Off 5 Years After Diagnosis
ODAC Says No to Gemzar for Ovarian Ca
Experts See Oncology Reimbursements Headed Down, Hard Negotiations With Payers Lie Ahead
Femara Effective Even After Years of No Therapy
XMRV Retrovirus Found in Some Prostate Ca's
Taxotere Wins FDA Approval for Advanced Gastric Cancer
Community Oncology Practices Struggle to Cope With the Extra Requirements of Medicare Part D
Director of NCI Nominated as New FDA Commissioner
TAM-01 Finds Longer Tamoxifen Duration Is Not Better
Erbitux Wins Approval for Squamous Cell H&N Cancer
Young Doctors Are Hungry for Psychological Oncology Training
Posaconazole Reduces Serious IFIs in High-Risk Patients
Recent Videos
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
Related Content
The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 8th 2025
Article

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.

The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.

Mosunetuzumab Exhibits Meaningful Responses in Untreated MZL

Roman Fabbricatore
September 5th 2025
Article

The safety and cytokine release syndrome profiles of mosunetuzumab were manageable in patients with previously untreated marginal zone lymphoma.